MAPK14 and chronic obstructive pulmonary disease: The compound, a p38 mitogen-activated protein kinase (MAPK) inhibitor, was initially developed to treat chronic obstructive pulmonary disease (COPD) and cardiovascular diseases (Norman, 2015; Segalés et al., 2016).